<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <title>Subchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism</title>
  <meta name="description" content="Autism spectrum disorder (ASD) is a group of pervasive developmental disorders with core symptoms such as sociability deficit, language impairment, and repet...">

  <link rel="stylesheet" href="/assets/main.css">

  <link rel="stylesheet" href="/assets/animate.css">

  <link rel="stylesheet" href="/assets/icomoon.css">

  <link rel="stylesheet" href="/assets/bootstrap.css">

  <link rel="stylesheet" href="/assets/superfish.css">

  <link href='https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,300' rel='stylesheet' type='text/css'>

  <link rel="stylesheet" href="/assets/style.css">

  <link rel="stylesheet" href="/assets/custom.css">

  <!-- Place favicon.ico and apple-touch-icon.png in the root directory -->
<!--  <link rel="shortcut icon" href="favicon.ico">-->

  <link href='https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,300' rel='stylesheet' type='text/css'>



  <link rel="canonical" href="http://localhost:4000/neuroventi/2014/08/18/Subchronic-treatment-of-donepezil.html">


  <link rel="alternate" type="application/rss+xml" title="Trineurotec" href="/feed.xml">


  
</head>

  <body>


    <div id="fh5co-wrapper">

<div id="fh5co-page">

  <nav class="navbar navbar--size--md navbar--color--white">
    <div class="container">
      <h1 class="navbar-text"><a href="../../../../../index.html"><span style="color:#00BCD4">Neuro</span>venti</a></h1>
      <div class="collapse navbar-collapse" id="mobileNav" style="margin-top: 11px;">
        <ul class="sf-menu sf-menu-venti" id="fh5co-primary-menu">
          <li>
            <a id="homeNav" href="../../../../../index.html">Home</a>
          </li>
          <li><a id="aboutNav" href="../../../../../about_venti.html" >About</a></li>
          <li><a id="whatNav" href="../../../../../what_venti.html" >What we do</a></li>
          <li><a id="productsNav" href="../../../../../products_venti.html" >Products</a></li>
          <li class="active"><a id="researchNav" href="../../../../../research_venti.html" >Research</a></li>
          <li><a id="contactNav" href="../../../../../contact_venti.html" >Contact</a></li>
        </ul>
      </div>
    </div>
  </nav>

  <div class="section" style="padding:70px 100px; font-family: "游ゴシック", YuGothic, "ヒラギノ角ゴ Pro", "Hiragino Kaku Gothic Pro", "メイリオ", "Meiryo", sans-serif;">
    <div class="container-research">
      <div class="post">

        <h3 class="post-title" style="font-size: 30px; font-weight: 300; line-height: 40px;">Subchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism</h3>
        <div class="post-info">
          <span>&nbsp;</span>Kim JW, Seung H, Kwon KJ, Ko MJ, Lee EJ, Oh HA, Choi CS, Kim KC, Gonzales EL, You JS, Choi DH, Lee J, Han SH, Yang SM, Cheong JH, Shin CY, Bahn GH

        </div>
        <br>
        <br>
        <div class="post-line"></div>

        <p>Autism spectrum disorder (ASD) is a group of pervasive developmental disorders with core symptoms such as sociability deficit, language impairment, and repetitive/restricted behaviors. Although worldwide prevalence of ASD has been increased continuously, therapeutic agents to ameliorate the core symptoms especially social deficits, are very limited. In this study, we investigated therapeutic potential of donepezil for ASD using valproic acid-induced autistic animal model (VPA animal model). We found that prenatal exposure of valproic acid (VPA) induced dysregulation of cholinergic neuronal development, most notably the up-regulation of acetylcholinesterase (AChE) in the prefrontal cortex of affected rat and mouse offspring. Similarly, differentiating cortical neural progenitor cell in culture treated with VPA showed increased expression of AChE in vitro. Chromatin precipitation experiments revealed that acetylation of histone H3 bound to AChE promoter region was increased by VPA. In addition, other histone deacetyalse inhibitors (HDACIs) such as trichostatin A and sodium butyrate also increased the expression of AChE in differentiating neural progenitor cells suggesting the essential role of HDACIs in the regulation of AChE expression. For behavioral analysis, we injected PBS or donepezil (0.3 mg/kg) intraperitoneally to control and VPA mice once daily from postnatal day 14 all throughout the experiment. Subchronic treatment of donepezil improved sociability and prevented repetitive behavior and hyperactivity of VPA-treated mice offspring. Taken together, these results provide evidence that dysregulation of ACh system represented by the up-regulation of AChE may serve as an effective pharmacological therapeutic target against autistic behaviors in VPA animal model of ASD, which should be subjected for further investigation to verify the clinical relevance.</p>

<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/25133713">Read More</a></p>


      </div>
    </div>
  </div>




</div>

</div>



    <footer class="site-footer">

  <div class="wrapper-footer">

    <h2 class="footer-heading">Trineurotec</h2>

    <div class="footer-col-wrapper">
      <div class="footer-col footer-col-1">
        <ul class="contact-list">
          <li>
            
              Trineurotec
            
            </li>
            
        </ul>
      </div>

      <div class="footer-col footer-col-2">
        <ul class="social-media-list">
        <!--  
          <li>
            <a href="https://github.com/trineurotec"><span class="icon icon--github"><svg viewBox="0 0 16 16" width="16px" height="16px"><path fill="#828282" d="M7.999,0.431c-4.285,0-7.76,3.474-7.76,7.761 c0,3.428,2.223,6.337,5.307,7.363c0.388,0.071,0.53-0.168,0.53-0.374c0-0.184-0.007-0.672-0.01-1.32 c-2.159,0.469-2.614-1.04-2.614-1.04c-0.353-0.896-0.862-1.135-0.862-1.135c-0.705-0.481,0.053-0.472,0.053-0.472 c0.779,0.055,1.189,0.8,1.189,0.8c0.692,1.186,1.816,0.843,2.258,0.645c0.071-0.502,0.271-0.843,0.493-1.037 C4.86,11.425,3.049,10.76,3.049,7.786c0-0.847,0.302-1.54,0.799-2.082C3.768,5.507,3.501,4.718,3.924,3.65 c0,0,0.652-0.209,2.134,0.796C6.677,4.273,7.34,4.187,8,4.184c0.659,0.003,1.323,0.089,1.943,0.261 c1.482-1.004,2.132-0.796,2.132-0.796c0.423,1.068,0.157,1.857,0.077,2.054c0.497,0.542,0.798,1.235,0.798,2.082 c0,2.981-1.814,3.637-3.543,3.829c0.279,0.24,0.527,0.713,0.527,1.437c0,1.037-0.01,1.874-0.01,2.129 c0,0.208,0.14,0.449,0.534,0.373c3.081-1.028,5.302-3.935,5.302-7.362C15.76,3.906,12.285,0.431,7.999,0.431z"/></svg>
</span><span class="username">trineurotec</span></a>

          </li>
          

          
          <li>
            <a href="https://twitter.com/trineurotec"><span class="icon icon--twitter"><svg viewBox="0 0 16 16" width="16px" height="16px"><path fill="#828282" d="M15.969,3.058c-0.586,0.26-1.217,0.436-1.878,0.515c0.675-0.405,1.194-1.045,1.438-1.809c-0.632,0.375-1.332,0.647-2.076,0.793c-0.596-0.636-1.446-1.033-2.387-1.033c-1.806,0-3.27,1.464-3.27,3.27 c0,0.256,0.029,0.506,0.085,0.745C5.163,5.404,2.753,4.102,1.14,2.124C0.859,2.607,0.698,3.168,0.698,3.767 c0,1.134,0.577,2.135,1.455,2.722C1.616,6.472,1.112,6.325,0.671,6.08c0,0.014,0,0.027,0,0.041c0,1.584,1.127,2.906,2.623,3.206 C3.02,9.402,2.731,9.442,2.433,9.442c-0.211,0-0.416-0.021-0.615-0.059c0.416,1.299,1.624,2.245,3.055,2.271 c-1.119,0.877-2.529,1.4-4.061,1.4c-0.264,0-0.524-0.015-0.78-0.046c1.447,0.928,3.166,1.469,5.013,1.469 c6.015,0,9.304-4.983,9.304-9.304c0-0.142-0.003-0.283-0.009-0.423C14.976,4.29,15.531,3.714,15.969,3.058z"/></svg>
</span><span class="username">trineurotec</span></a>

          </li>
          -->
        </ul>
      </div>

      <div class="footer-col footer-col-3">
        <p>No.1 drug development company for ADHD and other neurodevelopment disorders.
</p>
      </div>
    </div>

  </div>

</footer>



  </body>

</html>
